Jubilant Pharmova's Stellar Profit Surge

Jubilant Pharmova reported a 49% profit surge to Rs 103 crore for Q1 FY25, boosted by exceptional income. Revenue increased to Rs 1,901 crore. Chairman Shyam S Bhartia expressed optimism for continued growth. Shares were slightly down, trading at Rs 1,151.70 on BSE.

Jubilant Pharmova announced a remarkable 49% increase in profit after tax, reaching Rs 103 crore for the first quarter ending June 30, 2025, compared to Rs 69 crore in the same period last year.

The surge was influenced significantly by a one-time exceptional income of Rs 396 crore, enhancing the company's reported PAT to Rs 482 crore for Q1 of FY25. This financial boost accompanies a revenue rise to Rs 1,901 crore, compared to Rs 1,732 crore in the previous year.

Chairman Shyam S Bhartia conveyed optimism about the company's growth trajectory, while the shares of Jubilant Pharmova saw a minor decline of 1.88%, settling at Rs 1,151.70 apiece on the BSE.